Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
[DISCLOSURE] Macrogen (038290), a genome sequencing firm, announced on Sept. 21 that it has gained a patent for extracting fusion protein that encodes RET fusion protein which can be used as a diagnostic marker of cancer.
The patent includes primer pair of base sequence to detect KIF5B fusion protein and composite to inhibit activation of relevant fusion protein of lung cancer.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
The patent includes primer pair of base sequence to detect KIF5B fusion protein and composite to inhibit activation of relevant fusion protein of lung cancer.
By Yun Jeong-hyeon (clareyun@heraldcorp.com)
